Is dificlir (fidaxomicin) under patent?

Short answer:
The original patents covering the active ingredient fidaxomicin (brand name Dificlir) have expired, so generic versions of the drug are already on the market.
However, there are still some secondary patents (on specific dosage‑formulations, delivery systems, or combination therapies) that may still be in force in certain jurisdictions.

What’s happening with the core patents?

• Active‑ingredient patents (the chemical compound itself) generally expire 20 years after the first filing. The earliest filing for fidaxomicin was 1997, so the earliest expiry was 2017.
• Most of these patents have now lapsed, and the FDA has approved several generic manufacturers (Teva, Sandoz, others).

Are there still patents that matter?

Yes – but they’re not about the “fidaxomicin” molecule. They can involve:

These patents can affect which exact product can be sold, but they don’t stop generic manufacturers from producing the base drug in the approved capsule form.

What does this mean for you?

• Generic availability: In the U.S., Europe, Canada, and many other markets you can buy generic fidaxomicin at a lower cost.
• Patents on new forms: If a company wants to sell a new oral solution or a combination product, it may need to license the relevant secondary patents, even if the core drug is free.
• Regulatory status: The FDA (U.S.) and EMA (EU) still consider fidaxomicin a new drug with the brand name Dificlir, but generics are regulated under the generic drug pathway.

Practical advice

1. Check local patent registries if you’re interested in a specific formulation or a new combination.
2. Use trusted pharmacy sources for generics—they’re FDA‑approved and meet the same quality standards.
3. Consult a legal professional if you’re developing a new drug product or licensing a formulation, as patent law can be highly jurisdiction‑specific.

Disclaimer:
This answer is for informational purposes only and does not constitute legal advice. Patent status can change, and you should verify details with the USPTO or your national patent office before making business or clinical decisions.